 Edesa Biotech Inc NASDAQ: EDSA has announced additional results from the Phase 2 part of an ongoing Phase 23 study of EB05 as a single-dose treatment for hospitalized COVID-19 patients. Related: Edesa Biotech Provides Update For COVID-19 Antibody Trial. 